Arlington Capital Partners Makes Majority Investment in Everest Clinical Research Corporation

Everest Clinical Research (Arlington) Acquires August Research

November 7, 2023

Healthcare Services

Everest Clinical Research, a portfolio company of Arlington Capital Partners, has acquired European contract research organization August Research. The deal expands Everest's European footprint and clinical trial (CTS) and pharmacovigilance (PV) capabilities across 14 countries; August's founders will remain with the business. Financial terms were not disclosed.

Everest Clinical Research Acquires Brightech International

December 2, 2022

Healthcare Services

Everest Clinical Research, a PE-backed full-service contract research organization, has acquired Brightech International, a specialist CRO focused on biostatistics, statistical programming, and clinical data management. The deal strengthens Everest's biometrics capabilities and global footprint, complementing its therapeutic strengths in Oncology, CNS, and Immunology.

Cambridge Capital Makes Majority Investment in Everest Transportation Systems

September 8, 2021

Transportation

Cambridge Capital has made a majority investment in Everest Transportation Systems, a fast-growing freight brokerage headquartered in Evanston, Illinois. Everest's founders remain in leadership and retain significant ownership while Cambridge Capital partners to scale the business (including board seats for Benjamin Gordon and Matt Smalley), accelerate hiring and pursue tuck-in acquisitions; terms were not disclosed.

Arlington Capital Partners Makes Majority Growth Investment in CBSET

October 1, 2025

Healthcare Services

Arlington Capital Partners has completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies (CBSET), a Boston-area provider of preclinical translational research and product development services for medical device, pharmaceutical, diagnostic and biomedical research customers. The partnership will fund CBSET's capacity expansion, development of a new facility, capability build-out and pursuit of complementary add-on acquisitions to broaden its service offerings.

Arlington Capital Partners Makes Majority Investment in Afton Scientific

January 30, 2024

Pharmaceuticals

Arlington Capital Partners has made a majority investment in Afton Scientific, a Charlottesville-based CDMO specializing in sterile injectable drug manufacturing and related lab/packaging services. The partnership will support Afton's capacity growth and expansion of service offerings while founder and CEO Tom Thorpe remains a material shareholder and will continue to lead the company.

Edgewater Capital Partners Invests in CBCC Global Research

May 27, 2025

Healthcare Services

Edgewater Capital Partners, a Cleveland-based private equity firm, has partnered with the shareholders and management of CBCC Global Research, a Bakersfield-headquartered clinical contract research organization (CRO). Edgewater's investment will support CBCC's growth by funding people, technology, and infrastructure to expand its clinical trial services across oncology, CNS, ophthalmology and other therapeutic areas.